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empanelled with payers, clinicians, policy makers, health economists, and patient 
representatives. This study sought to identify trends in key advice and actionable 
information derived from HTAC meetings in North America, Europe, and Asia that 
influenced the development of pipeline products. Methods: Between 2010 and 
2013, 16 HTAC meetings were conducted for 14 Sanofi products in preclinical, Phase 
I and Phase II research. Six to 12 months after completion of each meeting, Clinical 
Development Leads completed a 15 question survey to identify the impact of HTAC 
on their projects. The results were collected and analyzed to determine the overall 
impact of the HTAC meetings. Results: A total of 14 surveys were completed. 
Advice and actionable information consisted of suggestions on clinical study design 
(36%), need of additional Health Economics and Outcomes Research (HEOR) studies 
(20%), and insights regarding pricing & reimbursement (11%). Feedback from HTAC 
influenced leadership committee decision-making (14%). Respondents agreed that 
the HTAC enabled important interactions with global experts early in development; 
moreover, all suggested that additional time be allowed to prepare for HTAC meet-
ings. All Clinical Development Leads indicated they would return to HTAC and rec-
ommend it to a colleague. ConClusions: The most frequent HTAC advice involved 
suggestions to improve clinical study design. HTAC also recommended performing 
additional HEOR studies. In many instances, feedback from HTAC influenced leader-
ship committee decision-making, such as licensing agreements.
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objeCtives: Health care expenditure in the United States is expected to be 19.9% of 
GDP by 2022 and professional services account for a substantial portion of the total 
health care spending. The study aims to decompose the source of spending variation 
in professional services across Texas hospital referral regions (HRRs) due to quan-
tity, price, health risk and cost of doing business. Methods: The study used 2011 
professional claims data for 3,829,083 members enrolled in Blue Cross Blue Shield 
(BCBS) of Texas, largest commercial insurance provider in Texas. Professional claims 
were classified into seven categories (i.e. evaluation and management, procedures, 
imaging, tests, durable medical equipment, other and exceptions/unclassified) using 
the Berenson-Eggers Type of Service (BETOS) code and Health Care Procedure Coding 
System (HCPCS) procedure codes. Geographic variation in spending per capita for 
each category was decomposed into quantity, price, cost of doing business and 
health risk. Results: Overall, spending variation in professional services is mainly 
explained by quantity (68.5%), followed by price (19.0%), cost of doing business (8.4%) 
and health risk (4.1%). Across categories, variation due to price was observed to be 
the highest for procedures (28.2%) and evaluation and management (22.4%) catego-
ries. Quantity accounted for majority of variation for imaging (80.5%), tests (83.2%), 
durable medical equipment (80.9%) and other (78.6%) categories. Contribution of 
health risk in explaining variation was relatively small for all professional subcate-
gories (range: 0.34% to 7.0%). ConClusions: Majority of the geographic variation in 
professional services spending was explained by quantity. However, contribution of 
quantity and price varied considerably in explaining geographic differences across 
different professional services. Further exploration is required in understanding 
factors that lead to such variations across service types.
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objeCtives: Reimbursement of brand drugs is typically set as a percentage of 
manufacturers’ listed prices. Thestudy evaluates trends the manufacturer listed 
prices at market entry of oral solid forms of new molecular entities (NMEs) approved 
by the US Food and Drug Administration (FDA) in the period 1990-2012. Methods: 
Drug regulatory information derived from the FDA. Daily defined dosages (DDD) 
were collected from the World Health Organization. Average wholesaler prices 
(AWP) per unit at market entry derived from the RedBook. Prices were converted 
to 2013 dollars using the consumer price index. Descriptive statistics, 95% con-
fidence intervals and t-tests were performed in the analysis. Results: The FDA 
approved 576 NMEs during the study period; 505 were marketed as of Dec 31, 
2013, and 339 had a solid oral form at approval. The analysis included 243 NMES 
withcomplete DDD and price information. There were 141 NMEs approved in the 
1990s, 82 in the 2000s and 20 in the period 2000-2013. The average AWP per DDD 
was $13.81±$31.99 (95%CI:$8.53-$19.09) in the 1990s, $45.54±$92.44 (95%CI:$25.53-
$65.55) in the 2000s, and $112.83±$175.27 (95%CI:$36.02-$189.64) in the period 
2010-2013. The average AWP per DDD was significantly higher (p= 0.001) for FDA 
priority review drugs ($59.01±$113.90, 95%CI:$34.80-$83.23, n= 85) than for standard 
review drugs ($18.50±$52.38, 95%CI:$10.33 $26.66). It was also higher (p= 0.005) for 
orphan drugs ($88.64± $112.85, 95%CI: $43.49-$133.79, n= 24) than for non-orphan 
drugs ($26.54± $75.27, 95%CI: $16.57-$36.50). Last, the AWP was significantly higher 
(p< 0.001) for drugs marketed as of December 2013 ($34.75±$84.66, 95%CI: $23.66-
$45.84, n= 224) than for discontinued drugs ($8.15±$5.30, 95%CI: $5.76-$10.53, 
opment, patient access scheme, drug reimbursement, risk management, clinical 
evidence development, real-world, real-life setting. Results: A total of 15 programs 
of risk management and development of real-world clinical evidence were ana-
lyzed. Of these programs, 6 were selected as relevant models for the province of 
Quebec. For 4 of these programs, ongoing in Canada, Australia and Europe, it was 
the manufacturer’s responsibility to develop and perform data collection. Otherwise, 
it was the responsibility of government agencies. For 100% of analyzed programs, 
a substantial financial participation from the manufacturer was required. Half of 
programs reported a direct participation of academic research institutions in the 
collection and processing of data while the other half did not mention their partici-
pation explicitly. Fifty percent of these programs were related to a reimbursement 
decision. ConClusions: This study indicated that the success of programs aiming 
to develop real-world clinical evidences involve active participation of academic 
research organizations as well as support from the manufacturers. These key ele-
ments should be considered in developing such a program in Quebec.
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objeCtives: The Ontario Drug Benefit (ODB) Formulary is the publicly funded pro-
vincial drug plan in Ontario. Drugs are included subsequent to a review of submitted 
clinical efficacy and pharmacoeconomic evidence by the Committee to Evaluate 
Drugs (CED). The objective of this analysis was to examine the degree to which 
economic evidence was utilized to inform drug reimbursement decision making 
in Ontario. Methods: All publicly available CED “Recommendation and Rationale” 
documents were reviewed to classify type of economic evidence, CED recommenda-
tions and rationales. Descriptiveand logistic regression analyses were conducted 
to examine the extent that economic evaluation impacts CED recommendations 
among other potential predictor factors. Results: A total of 123 separate recom-
mendations were retrieved (July 2007 to November 2012). Forty –seven percent 
received a fund recommendation while 53% received a do not fund recommenda-
tion. Almost all recommendations included some discussion of economic evidence; 
however complexity was limited to a discussion of price of therapy only for the 
majority (70%). Regression analysis found that documents including a discussion 
of economic evidence beyond price and statement of a price of therapy less than 
or similar to alternatives were more likely to result in positive recommendations 
(p < 0.05). ConClusions: Although economic evidence was routinely reviewed, 
discussion was usually limited to price of therapy. However, when pharmacoeco-
nomic evidence beyond price alone was discussed, a recommendation to fund by 
the CED was more likely.
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objeCtives: The Academy of Managed Care Pharmacy (AMCP) dossier format was 
introduced in 2000 to guide manufacturers in presenting evidence for new pharma-
ceuticals, biologics, and vaccines to gain reimbursement and/or formulary place-
ment in the United States (US) health care system. Limited information has been 
published on the role of these dossiers in health care decision making; therefore, 
this study aimed to characterize decision makers’ use of AMCP dossiers in access 
and formulary placement for new health technologies. Methods: We reviewed the 
published literature and third-party websites to identify how health care decision 
makers employ AMCP dossiers. We then developed a discussion guide for use in 
one-on-one interviews with medical and pharmacy directors involved in formulary 
decision making at a range of US health plans (national, regional, integrated). These 
interviews focused on how AMCP dossiers inform decision making and the useful-
ness of each dossier section. Results: Decision makers’ reports of the utility of 
AMCP dossiers varied greatly. Some decision makers use AMCP dossiers directly; 
others conduct research independent of the dossier. Pharmacy directors are more 
likely to use AMCP dossiers than medical directors, who typically are provided with 
briefs based partly on AMCP dossiers. Clinical study data, comparator information, 
and drug price are key in decision making. Decision makers are highly skeptical 
of AMCP dossier modeling sections and offered several suggestions to increase 
transparency and accountability. Great value is placed on succinctness and informa-
tion relevant to the disease area (e.g., in less-prevalent diseases). ConClusions: 
Although there are formal guidelines for AMCP dossiers, health care decision mak-
ers seek information tailored to the disease and technology. Given the varied use of 
AMCP dossiers in practice and the reality of US health care reform, clearly under-
standing payer use and perspectives is important. Brevity and accuracy are crucial 
for health care decision making.
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objeCtives: The research and development strategy for a new drug or device 
should be examined early in its clinical development to ensure that it ultimately 
delivers value for the patient, prescriber, and payer. The target product profile, clini-
cal study program, and value proposition for investigational products at Sanofi 
are evaluated regularly by an external Health Technology Advisory Council (HTAC) 
